Abstract:In the last two decades, morbidity and mortality of patients with chronic heart failure could be further reduced by improved pharmacological and cardiac device therapies. However, despite these advances, there is a substantial unmet need for novel therapies, ideally specifically addressing repair and regeneration of the damaged or lost myocardium and its vasculature, given the limited endogenous potential for renewal of cardiomyocytes in adults. In this respect, cardiac cell-based therapies have gained substantial attention and have entered clinical feasibility and safety studies a decade ago. Different cell-types have been used, including bone marrow-derived mononuclear cells, bone marrow-derived mesenchymal stem cells, mobilized CD34+ cells, and more recently cardiac-derived c-kit+ stem cells and cardiosphere-derived cells. Some of these studies have suggested a potential of cell-based therapies to reduce cardiac scar size and to improve cardiac function in patients with ischemic cardiomyopathy. While first clinical trials examining the impact of cardiac cell-based therapy on clinical outcome have now been initiated, improved understanding of underlying mechanisms of action of cell-based therapies may lead to strategies for optimization of the cardiac repair potential of the applied cells. In experimental studies, direct in vivo reprogramming of cardiac fibroblasts towards cardiomyocytes, and microRNA-based promotion of cardiomyocyte proliferation and cardiac repair have recently been reported that may represent novel therapeutic approaches for cardiac regeneration that would not need cell-administration but rather directly stimulate endogenous cardiac regeneration. This review will focus mainly on recently completed clinical trials (within the last 2 years) investigating cardiac cell-based therapies and the current status of experimental studies for cardiac cell-based repair and regeneration with a potential for later translation into clinical studies in the future.

Stem cell therapy for heart failure: Medical breakthrough, or dead end?

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

The Challenges Of Stem Cell Therapy In Myocardial Infarction And Heart Failure And The Potential Strategies To Improve The Outcomes

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Current Status of Stem Cell Therapy in Heart Failure

Stem Cell Therapy For Ischemic Heart Diseases

Stem cell therapy for cardiac regeneration: past, present, and future

Advances of Stem Cell Therapy to Treat Heart Failure

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction

Cell Therapy and 3D Regenerative Tissue to Remodel Heart Failure

Update on cardiac stem cell therapy in heart failure

Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

Current status of cell-based therapy for heart failure

Progenitor/stem Cell Transplantation for Repair of Myocardial Infarction: Hype or Hope?

Stem cell therapy for cardiac repair: benefits and barriers

Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types

The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease

Potential Mechanisms Underlying Therapeutic Benefits of Stem Cell for Heart Failure

Stem cells for heart failure in the aging heart

Current Optimized Strategies for Stem Cell-Derived Extracellular Vesicle/exosomes in Cardiac Repair.

Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure